MarketCap
Facebook
X
Telegram
Athersys Market Cap | ATHX
As of October 25, 2026 Athersys has a market cap of $ 22.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Athersys
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 8.07 M | 15.3 M | 182 M | 204 M | 154 M | 102 M | 146 M | 199 M | 218 M | 49.8 M | 46.9 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | 8.07 M | 120 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Nanobiotix S.A.
NBTX
|
1.45 T | $ 29.36 | 0.58 % | $ 1.4 T |  France |
 |
Viking Therapeutics
VKTX
|
3.18 B | $ 24.4 | -5.54 % | $ 2.75 B |  USA |
 |
Seer
SEER
|
123 M | $ 1.97 | 0.51 % | $ 109 M | USA |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 11.21 | 0.45 % | $ 1.21 B | USA |
 |
Nuvation Bio
NUVB
|
1.99 B | $ 4.57 | -2.45 % | $ 1.56 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 1.81 | -2.69 % | $ 2.37 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
24 B | $ 0.42 | 0.26 % | $ 5.18 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
203 M | $ 69.45 | 3.06 % | $ 193 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 11.54 | 1.67 % | $ 1.26 B | USA |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 13.4 | -1.25 % | $ 1.16 B | USA |
 |
Relay Therapeutics
RLAY
|
546 M | $ 18.18 | -0.87 % | $ 3.12 B | USA |
 |
Pfizer
PFE
|
155 B | $ 30.03 | -1.28 % | $ 171 B | USA |
 |
Sutro Biopharma
STRO
|
181 M | $ 9.33 | -9.33 % | $ 79.3 M | USA |
 |
Shattuck Labs
STTK
|
349 M | $ 5.49 | -1.96 % | $ 382 M | USA |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 186.99 | -0.37 % | $ 35.6 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 89.27 | -1.79 % | $ 5.8 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
277 M | $ 3.63 | 0.83 % | $ 279 M | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 2.33 | -1.69 % | $ 590 M | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
855 M | $ 2.02 | 2.54 % | $ 1.36 B | Israel |
 |
Pulmatrix
PULM
|
5.08 B | $ 1.48 | 4.23 % | $ 5.41 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
2.01 B | $ 15.65 | -1.88 % | $ 1.54 B | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
56.9 M | - | -7.31 % | $ 49 M | USA |
|
Protara Therapeutics
TARA
|
245 M | $ 2.33 | -4.51 % | $ 99.8 M | USA |
 |
AC Immune SA
ACIU
|
287 M | $ 2.42 | -3.2 % | $ 244 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
616 M | - | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
224 M | $ 2.41 | -1.23 % | $ 142 M |  China |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 3.92 | -7.11 % | $ 2.62 M | USA |
 |
Zai Lab Limited
ZLAB
|
21.6 B | $ 24.03 | 9.03 % | $ 26.3 B | China |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 10.68 | -2.47 % | $ 2.55 B | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
192 M | $ 2.21 | -8.3 % | $ 159 M | USA |
 |
Zymeworks
ZYME
|
845 M | $ 28.22 | -0.77 % | $ 1.45 B |  Canada |
 |
Zoetis
ZTS
|
56.1 B | $ 81.03 | -1.18 % | $ 35.9 B | USA |
 |
Assembly Biosciences
ASMB
|
308 M | $ 19.84 | -2.17 % | $ 222 M | USA |
 |
Allogene Therapeutics
ALLO
|
545 M | $ 1.25 | -1.6 % | $ 276 M | USA |
 |
Amgen
AMGN
|
198 B | $ 439.26 | -1.79 % | $ 236 B | USA |
 |
Ardelyx
ARDX
|
1.62 B | $ 3.08 | -3.75 % | $ 742 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
312 M | $ 3.64 | 5.51 % | $ 132 M | USA |
 |
Artelo Biosciences
ARTL
|
255 K | $ 2.55 | 2.75 % | $ 482 K | USA |
 |
Biofrontera AG
BFRA
|
220 M | - | -8.24 % | $ 105 M |  Germany |
 |
Bicycle Therapeutics plc
BCYC
|
351 M | $ 3.55 | -2.47 % | $ 246 M |  Britain |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
80.6 M | - | -6.97 % | $ 657 M | USA |
 |
Beam Therapeutics
BEAM
|
3.2 B | $ 24.05 | -2.08 % | $ 2.38 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
4.56 B | - | 1.68 % | $ 4.65 B | China |
 |
Benitec Biopharma
BNTC
|
562 M | $ 8.65 | -1.93 % | $ 403 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 88.12 | -1.73 % | $ 21.3 B | Germany |
 |
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 72.61 | -1.55 % | $ 1.46 B | USA |
 |
C4 Therapeutics
CCCC
|
234 M | $ 3.06 | -3.77 % | $ 254 M | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.33 | 0.87 % | $ 444 M | USA |
 |
Certara
CERT
|
1.08 B | $ 10.33 | 2.38 % | $ 1.66 B | USA |
 |
Flexion Therapeutics, Inc.
FLXN
|
521 M | - | - | $ 459 M | USA |